title: [Intensified risk monitoring of new drugs in general practice by the established physician].
authors.forename: R
authors.initials: R
authors.lastname: Hanpft
authors.forename: M
authors.initials: M
authors.lastname: Hannig
mesh_terms: D000806:Angiotensin-Converting Enzyme Inhibitors / Q000009:adverse effects*; D000900:Anti-Bacterial Agents / Q000009:adverse effects*; D005860:Germany, West; D006635:Histamine H2 Antagonists / Q000009:adverse effects*; D006801:Humans; D011358:Product Surveillance, Postmarketing; D012307:Risk Factors; D059005:Topoisomerase II Inhibitors
chemical_list: D000806:Angiotensin-Converting Enzyme Inhibitors; D000900:Anti-Bacterial Agents; D006635:Histamine H2 Antagonists; D059005:Topoisomerase II Inhibitors
vernacular_title: Intensivierte Risikoüberwachung neuer Arzneimittel in der Praxis des niedergelassenen Arztes.